Eastwood Bio-Medical Canada (EBM) AI Stock Analysis

• Market Cap: C$58.55M
• Dividend Yield: N/A
• Average Volume (3M): 3.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: -9.02%
• EPS Growth: 14.29%
• Country: CA
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Food Distribution
• EPS (TTM): N/A
• Shares Outstanding: 68,885,970
• 10 Day Avg. Volume: 3,055
• 30 Day Avg. Volume: 3,488
• PEG Ratio: 5.31
• Price to Book (P/B): -29.59
• Price to Sales (P/S): 61.66
• P/FCF Ratio: 2.50K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.89 ▲(11.37% Upside)
• Action: Reiterated Date: 04/08/26
• Date: Action: Reiterated 04/08/26

The score is held down primarily by very weak financial performance (persistent large losses, declining TTM revenue, and negative equity), with only limited improvement from small positive recent free cash flow. Technicals are supportive (price above major moving averages and positive MACD), but momentum indicators are near stretched levels. Valuation remains unattractive/unclear because earnings are negative (P/E not meaningful) and no dividend yield is provided.

Positive Factors

High gross margin

A ~63% gross margin indicates attractive unit economics for the Eleotin product line and inherent pricing power on formulations. Sustained high gross margins give management flexibility to invest in marketing, R&D, or scale while still having a clear path to recover operating profitability if SG&A is controlled.

Negative Factors

Negative shareholders' equity

Material negative equity (~-$1.65M) signals structural balance-sheet weakness and raises solvency and covenant risks. It limits financial flexibility, makes external financing more costly or scarce, and creates a persistent overhang that can impede investment, partnerships, or scaling without capital repairs.

Eastwood Bio-Medical Canada Business Overview & Revenue Model

Company Description

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose di...

Read more

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose di...

How the Company Makes Money

Eastwood Bio-Medical Canada (EBM) generates revenue primarily through the sale of its Eleotin-branded natural health supplements. These products are distributed through various channels, including online stores, retail partners, and direct custome...

Read more

Eastwood Bio-Medical Canada (EBM) generates revenue primarily through the sale of its Eleotin-branded natural health supplements. These products are distributed through various channels, including online stores, retail partners, and direct custome...

Eastwood Bio-Medical Canada Financial Statement Overview

Breakdown	Jan 2026	Jan 2025	Oct 2023	Oct 2022	Jan 2022
Income Statement
Total Revenue	782.08K	702.08K	867.94K	1.30M	981.05K
Gross Profit	506.03K	454.39K	440.51K	902.74K	458.37K
EBITDA	-309.73K	-342.05K	-410.58K	-32.33K	-495.50K
Net Income	-332.77K	-455.87K	-546.60K	-160.58K	-611.34K
Balance Sheet
Total Assets	218.77K	274.29K	489.14K	584.53K	691.12K
Cash, Cash Equivalents and Short-Term Investments	17.70K	0.00	18.45K	39.84K	20.87K
Total Debt	78.01K	79.61K	23.08K	62.25K	31.35K
Total Liabilities	1.85M	1.57M	1.33M	878.73K	835.44K
Stockholders Equity	-1.63M	-1.30M	-840.80K	-294.20K	-144.32K
Cash Flow
Free Cash Flow	19.30K	-15.22K	-16.89K	-7.30K	-121.79K
Operating Cash Flow	19.30K	-15.22K	-16.89K	-4.29K	-116.21K
Investing Cash Flow	0.00	0.00	0.00	-3.00K	-5.57K
Financing Cash Flow	-211.00	-4.62K	-4.50K	26.27K	20.00K

Eastwood Bio-Medical Canada Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Positive. The current price of 0.8 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.74, and above the 200-day MA of 0.63, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 59.51 is Neutral, neither overbought nor oversold. The STOCH value of 66.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EBM.

Eastwood Bio-Medical Canada Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
ATLE	50 Neutral	C$58.12M	-6.04	-19.76%	―	26.91%	81.01%
EBM	48 Neutral	C$58.55M	-498.55	―	―	-9.02%	14.29%
ADK	45 Neutral	C$30.71M	-9.48	3086.87%	―	-48.53%	-9.66%
SONA	41 Neutral	C$34.31M	-16.88	-434.25%	―	―	10.97%
ARCH	39 Underperform	C$37.48M	-12.93	72.34%	―	―	10.49%